INmune Bio to host Nov 7 webinar on EMACC cognitive tool for Alzheimer's trials

Inmune Bio, Inc.

Webinar on Nov 7, 2024 at 1 PM ET, titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials."
Poster on EMACC sensitivity and performance in Phase II Alzheimer's trial presented at CTAD2024.
Company is conducting a Phase II trial of XPro in early AD using EMACC and CDR-SB as endpoints.
No financial results, clinical data readouts, or material business changes disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.